Drug intelligence / Profile preview

carboplatin + paclitaxel albumin-bound + sorafenib

Development stage: Unknown
Lead developer: Bayer
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous, Oral

Overview

This combination therapy regimen consists of carboplatin, ABI-007 (Abraxane), and sorafenib. ABI-007 is an albumin-stabilized nanoparticle formulation of paclitaxel that functions as a microtubule stabilizer, inhibiting cell division. Carboplatin is a platinum-based antineoplastic agent that induces DNA cross-linking, leading to apoptosis. Sorafenib is a small-molecule multikinase inhibitor that targets Raf kinases (C-Raf, B-Raf) and various receptor tyrosine kinases involved in tumor growth and angiogenesis, including VEGFR and PDGFR. This specific combination was investigated in a Phase II clinical trial led by Mt. Sinai Medical Center, Miami, specifically for patients with stage III or IV metastatic malignant melanoma.

Brand names: AbraxaneNexavar
Other names: ABI-007-Mt. Sinai Medical Center, Miami-malignant melanomanab-paclitaxelnanoparticle albumin-bound paclitaxel

Targets

BRAF (B-Raf proto-oncogene, serine/threonine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))DNAVEGFR3 (Vascular endothelial growth factor receptor 3)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on carboplatin + paclitaxel albumin-bound + sorafenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + paclitaxel albumin-bound + sorafenib.

Explore the full profile